2026 Life Sciences Outlook

Deloitte’s 2026 Life Sciences Outlook Survey reveals that while over 75% of biopharma and medtech executives are confident in their own organizations' financial performance, only 41% feel optimistic about the broader global economy. The report highlights a significant regional divide in sentiment, with European and Asian biopharma leaders showing much higher levels of optimism compared to their counterparts in the United States. For the healthcare and biotech sector, the coming year will likely demand a balance between aggressive investments in artificial intelligence and the agility to navigate complex regulatory and geopolitical shifts.

The fourth annual survey, conducted by the Deloitte US Center for Health Solutions and Deloitte Global, gathered insights from 280 C-suite executives across the United States, Europe, and Asia between August and September 2025. The findings indicate that 90% of biopharma leaders in Europe and Asia maintain a positive or cautiously positive outlook for 2026, with 83% predicting steady or strong revenue growth. In contrast, US-based biopharma executives are more reserved, with only 56% expressing positive sentiment and 18% anticipating a decline in revenue. This disparity suggests that while the industry is increasingly borderless, regional regulatory environments and economic conditions are creating divergent paths for growth.

Medtech executives generally report higher levels of optimism than their biopharma peers, with 81% overall expecting revenue growth. Unlike the biopharma sector, medtech sentiment is relatively consistent across geographies, showing no statistically significant difference between US executives at 84% growth expectation and those in international markets at 78%. Industry leaders, including Pete Lyons, national sector leader for Deloitte’s Life Sciences practice, and Sheryl Jacobson, who leads the medtech practice, emphasize that success in 2026 will require innovative thinking and robust external partnerships to sustain growth amidst persistent pricing pressures and regulatory shifts.

The report identifies a shift from US-centric growth strategies toward a more fragmented global landscape where companies must make nuanced decisions regarding product advancement and pricing. Executives are increasingly focused on building agility muscles to mitigate risks associated with geopolitical tensions and economic volatility, as noted by a European strategy executive who highlighted the importance of a diversified footprint. Gabriele Ricci, chief data and technology officer at Takeda Pharmaceuticals, further observed that such volatility can fuel innovation. To capitalize on future opportunities, organizations are expected to prioritize bold investments in emerging technologies like artificial intelligence while maintaining the pragmatic ability to adapt to a rapidly changing global market.